According to CytRx, Levin has spent the last four years at the firm of O'Melveny & Myers as a transactional lawyer. He graduated from
Proteomics company Power3 has appointed Zouhair Atassi and Thomas Watts to the company's scientific advisory board.
Atassi is currently chair of chemistry and professor of biochemistry and molecular biology at the
Watts is a resident physician at the Kelsey-Seybold Clinic in The Woodlands, Tex. Watts practiced medicine at the
Steve Lombardi is the new non-executive director of IntegraGen, the company said. Lombardi is currently senior vice president of corporate development at Affymetrix. Prior to these, he spent 16 years at Applied Biosystems, finishing his career there as senior vice president of applications and products.
Guava Technologies has named David King as vice president of product development, the company said last week.
King joins Guava from Iolon, a privately-held manufacturer of tunable optical components, where he was head of new product development and product integration. Prior to this, he was principal engineer at Agilent Technologies. He has also been employed by Hewlett Packard.
King received his MS and PhD in applied physics from
William Spencer has joined Branford, Conn.-based 454 Life Sciences as strategic marketing manager. Spencer joins 454 from OpGen, where he most recently served as director of business development.
Pharmacopeia Drug Discovery has named Leslie Brown as president and chief executive officer, the company announced last week.
Most recently, Brown served as chief operating officer at Iconix Pharmaceuticals. He has also been the chief operating officer at functional genomics company GeneTrace. From 1990 to 2000, Brown held a number of senior positions at Berlex/Schering AG including corporate vice president of Berlex Labs and president of Schering Berlin Venture.
Brown received his PhD from the
Congressman James Greenwood, who recently held hearings on Capitol Hill to see whether two proteomics researchers at the National Cancer Institute violated conflict of interest rules, will leave the US House of Representatives to become president of the Biotechnology Industry Organization. He replaces Carl Feldbaum.
Greewood, who represents